Hansa Biopharma AB (publ) (HNSBF) Projected to Announce Earnings on Wednesday

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) will likely be posting its resultson Wednesday, July 22nd. Analysts expect the company to announce earnings of ($0.0346) per share and revenue of $5.17 million for the quarter.

Hansa Biopharma AB (publ) Stock Performance

OTCMKTS:HNSBF opened at $2.90 on Wednesday. Hansa Biopharma AB has a fifty-two week low of $2.90 and a fifty-two week high of $2.90. The company’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $2.90.

Analysts Set New Price Targets

Separately, Danske started coverage on shares of Hansa Biopharma AB (publ) in a research report on Tuesday, June 16th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hansa Biopharma AB (publ) currently has an average rating of “Buy”.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.